Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by weakness, muscle atrophy and spasticity related to the selective loss of motor neurons in the cortex, brain stem and spinal cord, is the most common adult motor neuron disease. Approximately 5-10% of ALS cases are familial, and except for mutations in SOD1 that cause a subset of familial ALS, the etiology of ALS is largely unknown. The identification of specific genes causing ALS allows generation of animal models for studies of disease mechanisms to facilitate the design of rationale therapy for treatment of this devastating illness. Recently, a missense mutation (G59S) in a gene encoding the largest subunit of dynactin complex, termed p1509'U8d, was identified in a large family that associates with slowly progressive lower motor neuron disease. Although mutant dynactin p15CPlued alleles are inherited in an autosomal dominant fashion, suggesting that the disease may result from a toxic gain of function, initial in vitro studies indicated that disease linked mutant p150glued possessed a reduced binding efficiency to microtubules, indicating a partial loss of function. To begin to clarify the mechanism whereby mutant p1509lued causes selective motor neuron disease, we plan to take a genetic approach to first generate human wild type and mutant dynactin transgenic mice and characterize the consequences of expression of mutant p1509lued in mice. In addition, we plan to generate and characterize dynactin p150P'ued standard knockout mice by deleting the gene encoding dynactin p1509'UBd. We hypothesize that mutant, but not wild type dynactin p15CPlued mice will lead to clinical and neuropathological outcomes that are consistent with motor neuron disease whereas mice lacking one allele of dynactin p15QPlued are normal. Such outcomes would be consistent with the idea that ALS-linked mutant p1509'ued causes disease through a gain of function mechanism. Finally, since dynactin is involved in axonal transport, we will examine whether mutant dynactin p1509lued impacts on either anterograde or retrograde axonal transport in these wild type and mutant dynactin p15CPluf>d mice. Taken together, these efforts will clarify the mechanism whereby mutant dynactin p15CPlued causes motor neuron disease and will have the potential to identify novel therapeutic targets and allow design of drug treatments for motor neuron disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS040014-10
Application #
8062029
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Gubitz, Amelie
Project Start
2000-04-10
Project End
2012-03-31
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
10
Fiscal Year
2011
Total Cost
$351,575
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wiesner, Diana; Sinniger, Jérome; Henriques, Alexandre et al. (2015) Low dietary protein content alleviates motor symptoms in mice with mutant dynactin/dynein-mediated neurodegeneration. Hum Mol Genet 24:2228-40
Chiang, Po-Min; Wong, Philip C (2011) Differentiation of an embryonic stem cell to hemogenic endothelium by defined factors: essential role of bone morphogenetic protein 4. Development 138:2833-43
Chiang, Po-Min; Ling, Jonathan; Jeong, Yun Ha et al. (2010) Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc Natl Acad Sci U S A 107:16320-4
Shan, Xiu; Chiang, Po-Min; Price, Donald L et al. (2010) Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A 107:16325-30
Laird, Fiona M; Farah, Mohamed H; Ackerley, Steven et al. (2008) Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J Neurosci 28:1997-2005
Lai, Chen; Xie, Chengsong; McCormack, Stefanie G et al. (2006) Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking. J Neurosci 26:11798-806
Cai, Huaibin; Lin, Xian; Xie, Chengsong et al. (2005) Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress. J Neurosci 25:7567-74
Liu, Jian; Lillo, Concepcion; Jonsson, P Andreas et al. (2004) Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 43:5-17
Carroll, Mark C; Girouard, Jody B; Ulloa, Janella L et al. (2004) Mechanisms for activating Cu- and Zn-containing superoxide dismutase in the absence of the CCS Cu chaperone. Proc Natl Acad Sci U S A 101:5964-9
Wong, Philip C; Cai, Huaibin; Borchelt, David R et al. (2002) Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci 5:633-9

Showing the most recent 10 out of 11 publications